Hyperpolarized 129XeMRI Imaging for Severe Asthma in Obesity
What You Need to Know Before You Apply
What is the purpose of this trial?
40% of all asthma patients in the US are obese. Obese asthmatics have more severe disease than lean asthmatics and do not respond as well to conventional anti-inflammatory therapies. This proposal will utilize 3D functional imaging with 129XeMRI and single cell RNA sequencing to study mechanisms driving regional airway remodeling and fibrosis in obese asthma subjects and in preclinical models of obese asthma.
Who Is on the Research Team?
Loretta Que, MD
Principal Investigator
Duke
Are You a Good Fit for This Trial?
This trial is for adults aged 18-65 with asthma and a BMI ≥30 kg/m2, who have been on stable asthma medication for at least 3 months. Non-smokers or those who haven't smoked in the last 3 months are eligible. Participants must be able to perform spirometry tests and give informed consent. Pregnant women, individuals with significant illnesses like heart disease or uncontrolled diabetes, or those unable to complete study assessments are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Imaging and Baseline Assessment
Participants undergo 3D functional imaging with 129XeMRI and baseline assessments to identify airway remodeling and fibrosis
Treatment
Participants receive interventions based on imaging results to study mechanisms driving regional airway remodeling and fibrosis
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Hyperpolarized 129XeMRI
Find a Clinic Near You
Who Is Running the Clinical Trial?
Bastiaan Driehuys
Lead Sponsor
National Institutes of Health (NIH)
Collaborator